Stem Cells
Summary
Stem cell transplants are routinely used to treat patients with cancers and other disorders of the blood and the immune system and may hold the key to repairing or replacing tissue cells damaged in many devastating diseases. Thus, proven and potential clinical benefit underpins the vast interest in stem cell research. Stem cells have both the capacity to self-renew (by cell division) and differentiate into mature, specialized cells. Differentiation describes a process of development with an increase in the level of organisation or complexity of a cell, accompanied with a more specialized function. During differentiation, certain genes become activated and other genes become inactivated in an intricately regulated fashion. As a result, a differentiated cell develops specific structures and performs certain functions.
This new report provides pharmaceutical companies with a clear assessment of opportunities and challenges presented to them by the stem cell market. It also provides vital insights into stem cell technologies and therapies that have already proven to be successful and analyzes those which have potential future value. The regulatory climate and proprietary landscape are discussed enabling you to formulate and optimize your stem cell strategies and position yourself for growth in this emerging market. Use this latest report to recognize areas poised for growth in the market for tissue repair and regeneration, identify potential alliance partners and plan a long-term growth strategy to secure your leading position in this market.
Key Features
· Growth forecasts for stem cell market sub-sectors to 2010.
· Examination of proprietary technologies and company strategies shaping the market for adult, embryonic and fetal stem cell products.
· Discussion of opportunities arising out of advances in hematopoietic stem cell transplantation.
· Analysis of global regulatory issues which are dictating where and how embryonic stem cell research is being done.
Key Findings
· The market for stem cell products and services is forecast to grow almost three-fold from $24.6 billion in 2005 to $68.9 billion in 2010.
· During the years 1980-2005, over 2,000 US patents claiming stem cell technologies and applications relevant to healthcare were published; the annual publication rate accelerated sharply in 2002.
· The proportion of stem cell patents claiming applications in hematology decreased after 1999, while the proportion of patents claiming applications in neurology, type 1 diabetes, cardiology and drug screening increased.
· Over 100 companies with proprietary human adult stem cell technologies and products have been identified.
The stem call market is emerging and growing rapidly as medical science continues to find more and better ways to use stem cells to solve life threatening disease. More and more parents are preserving umbilical cord stem cells of their newborn children for future use. The cost is around $3,000.
The safe and effective storage of stem cells is critical to the research and their use in health care. Stem Cells are stored through a process called cryopreservation at temperatures ranging from -37C to -87C.
Industry data indicates that only 20% survive cryopreservation.
Laboratory testing shows that healthy and safe storage of stem cells is significantly improved to close to 100% when AAGP™ is added to the cryopreservation process.
Put simply, more and healthier stem cells will be available for use at a later date when they are needed.
The market for stem cell products and services is forecast to grow almost three-fold from $24.6 billion in 2005 to $68.9 billion in 2010.
During the years 1980-2005, over 2,000 US patents claiming stem cell technologies and applications relevant to healthcare were published; the annual publication rate accelerated sharply in 2002.
The proportion of stem cell patents claiming applications in hematology decreased after 1999, while the proportion of patents claiming applications in neurology, type 1 diabetes, cardiology and drug screening increased.
Over 100 companies with proprietary human adult stem cell technologies and products have been identified.
